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Abstract
Background: Early identification and control of pathogenic bacteria are important in the treatment of pneumonia.
Currently, two rapid antigen detection kits for pneumococcal pneumonia are available: one uses urine samples and
the other, named RAPIRUN® S. pneumoniae, uses sputum samples. RAPIRUN® has shown high sensitivity with
nasopharyngeal swab samples from pediatric patients. In this study, we investigated the performance of
RAPIRUN® with nasopharyngeal swabs from adult patients.
Methods: All adult patients diagnosed with pneumonia from November 2011 to April 2012 in St. Luke’s
International hospital were included in this cross-sectional study. Single sputum, nasopharyngeal swab, and
urine samples obtained from patients were investigated using a rapid antigen detection kit. Sputum and
blood cultures were also evaluated. We compared the characteristics of pneumococcal pneumonia patients
diagnosed using RAPIRUN with a nasopharyngeal swab to those patients diagnosed using other methods.
Sensitivity and specificity were also calculated.
Results: Seventeen out of 60 patients with pneumonia were diagnosed with pneumococcal pneumonia. In 4
out of the 17 cases, a positive test result was obtained using RAPIRUN with a nasopharyngeal swab. The
sensitivity and specificity were 23.5 and 100 %, respectively.
Conclusion: RAPIRUN performed with nasopharyngeal swabs from adult patients exhibited lower sensitivity
for the diagnosis of pneumococcal pneumonia than the other compared methods. The causative pathogen of
pneumonia should be identified using not only sputum cultures or rapid antigen detection kits but also
clinical features or gram staining of sputum.
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Background
Pneumonia was the fourth most common cause of death
worldwide in 2012 [1], and it is a critical illness especially
for the elderly because of increase in its incidence and
severity [2]. The most common causative pathogen of
pneumonia is Streptococcus pneumoniae, which causes a
serious form of pneumonia [3, 4]. Although pneumococcal
vaccination is an efficient prevention strategy against
pneumococcal pneumonia, the vaccine does not cover all
serotypes of S. pneumoniae [5]. Thus, early identification
of the pathogenic bacteria and appropriate initial treat-
ment remain important to an optimal outcome.
Currently, two rapid detection kits for S. pneumoniae
antigen are available: BinaxNOW® S. pneumoniae, which
uses urine samples, and an immunochromatographic
ODK0501 assay named RAPIRUN® S. pneumoniae,
which uses sputum and nasopharyngeal swab samples
(hereafter referred to as BinaxNOW and RAPIRUN,
respectively). It has been reported that the use of Binax-
NOW with urine samples and RAPIRUN with sputum
samples from adult pneumonia patients shows high
efficiency in the diagnosis of pneumococcal pneumonia
[6–10]. In addition, RAPIRUN performed with sputum
samples shows higher sensitivity than BinaxNOW [9, 10].
However, RAPIRUN requires good quality sputum to
achieve higher sensitivity [11], and the sensitivity of
RAPIRUN might be lower in the elderly, who have diffi-
culty coughing up sputum.
RAPIRUN has also been found to exhibit high sensi-
tivity for pneumococcal pneumonia when used with
nasopharyngeal swabs from pediatric patients [12]. How-
ever, the efficiency of RAPIRUN with nasopharyngeal
swabs from adult patients has not been reported. In this
study, we investigated the performance of RAPIRUN
with nasopharyngeal swabs for the diagnosis of pneumo-
coccal pneumonia in adult patients.
Methods
Patient population and diagnostic criteria
The St. Luke’s International Hospital Research Ethics
Committee approved all aspects of this study (approval
number 11-R127, approval date October 24, 2011). This
was a cross-sectional study conducted at St. Luke’s Inter-
national Hospital, Tokyo, Japan, from November 2011 to
April 2012. Written informed consent was obtained from
60 consecutive patients who were over 20 years old and
were hospitalized with a diagnosis of pneumonia.
Pneumonia was defined as new infiltrates on a chest
radiograph with symptoms indicating lower respiratory
tract infection, such as cough, sputum, fever, or dyspnea.
Sample collection and microbiological investigation
Single sputum, urine, and nasopharyngeal swab samples
were collected from the patients. Nasopharyngeal swab
samples were collected by inserting swab into a nostril
straight back along the floor of the nasal passage until
reaching the posterior wall of the nasopharynx. Sputum
and nasopharyngeal swab samples were analyzed using
RAPIRUN® (Otsuka Pharmaceutical Co., Ltd., Tokyo,
Japan). We also analyzed the urine samples using the
BinaxNOW® rapid antigen detection kit (Binax Inc.,
Scarborough, ME, USA). Sputum, nasopharyngeal, and
blood cultures were also evaluated.
Using RAPIRUN®
We used swabs to collect sputum and nasopharyngeal
samples, and the extraction solutions were added to the
test kit. Two lines indicated a positive result, i.e., the test
and control, and a negative result showed only the control
line. This test required approximately 25 min in total.
Data collection
In addition to bacterial information, we collected clinical
data, such as those pertaining to age, sex, smoking
habits, existing underlying diseases, residence, history of
pneumococcal vaccination, prior antibiotic therapy, vital
signs, medication, laboratory testing, and chest radio-
graphs, at admission. We also calculated the Patient
Outcomes Research Team (PORT) score.
Diagnosis of pneumococcal pneumonia
Sputum culture is the most commonly used reference
standard for the detection of the causative pneumonia
pathogens, but both the sensitivity and specificity are
not sufficient [13, 14]. We determined the causative
pneumonia pathogen using a combination of multiple
diagnostic test results, that is the results for sputum cul-
ture, blood culture, and a rapid antigen detection kit
(RAPIRUN with sputum and BinaxNOW with urine). A
diagnosis of pneumococcal pneumonia was made if any
test results showed evidence of S. pneumoniae.
Analysis
We compared the characteristics of patients with
pneumococcal pneumonia with those of patients with
pneumonia caused by other pathogens using Fisher’s
exact probability test or Mann-Whitney’s U test (two
tailed, with a p of < 0.05 indicating a significant
difference).
We also compared the patients with pneumococcal
pneumonia diagnosed using RAPIRUN with a nasopha-
ryngeal swab with those diagnosed using other methods.
The sensitivity and specificity of RAPIRUN performed
with a nasopharyngeal swab for diagnosing pneumococ-
cal pneumonia were also calculated.
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Results
We collected samples from 60 consecutive inpatients
with pneumonia. Due to anuria in cases of end-stage
renal failure, urine samples were obtained from only
58 patients. The average age of all patients was 81
(28–96) years, and more than half of the patients
were male (58.3 %) and smokers (55.0 %). Commonly,
observed underlying diseases included diabetes melli-
tus, chronic obstructive pulmonary disease, and ma-
lignant neoplasm. Thirteen out of 60 (21.7 %)
patients had received the 23-valent pneumococcal
polysaccharide vaccine.
Seventeen out of 60 (28.3 %) patients had been diag-
nosed with pneumococcal pneumonia. For the 17 cases
of pneumococcal pneumonia, 14 cases were positive
using BinaxNOW, 12 cases were positive using
RAPIRUN with sputum samples, 10 cases were positive
for S. pneumoniae in the sputum culture, and one case
was positive for S. pneumoniae in the blood culture.
Table 1 lists the patients’ characteristics. C-reactive pro-
tein was significantly higher in patients with pneumo-
coccal pneumonia than in patients with pneumonia
caused by other bacteria. The proportion of patients
who received a pneumococcal vaccine was lower in pa-
tients with pneumococcal pneumonia, but this differ-
ence was not significant.
Results of RAPIRUN with nasopharyngeal swabs
Out of the 60 patients who participated in this study,
only four patients showed positive test results when
using RAPIRUN with nasopharyngeal swabs. The char-
acteristics of these four patients and the results of the
microbiological investigations are shown in Tables 2 and
3, respectively. All four cases were diagnosed as
pneumococcal pneumonia using BinaxNOW performed
with a urine sample or RAPIRUN performed with a spu-
tum sample. Interestingly, only two patients had positive
nasopharyngeal culture for S. pneumoniae among four
cases with positive result of RAPIRUN with a nasopha-
ryngeal swab. There was an insufficient number of pa-
tients; however, the sensitivity and specificity of
RAPIRUN with a nasopharyngeal swab were calculated
as 23.5 and 100 %, respectively.
Discussion
We diagnosed 17 patients as having pneumococcal
pneumonia, and only four of these patients showed posi-
tive results when using RAPIRUN with nasopharyngeal
swabs, suggesting low sensitivity, although RAPIRUN
with sputum samples previously showed high sensitivity
[10]. Iwata et al. [12] reported that RAPIRUN exhibited
high sensitivity (33/50, 66 %) and specificity (55/55,
100 %) when used with nasopharyngeal swabs in





Pneumonia caused by other
bacteria (n = 43)
P
Age, years, median (range) 81 (28–96) 78 (28–96) 82 (40–96) 0.45
Male sex, n (%) 35 (58.3) 7 (41.2) 28 (68.3) 0.15
Nursing home residents, n (%) 8 (13.3) 0 0 8 (19.5) 0.091
Smoking history, n (%) 33 (55.0) 7 (41.2) 26 (63.4) 0.25
Patients with underlying disease
Diabetes mellitus, n (%) 14 (23.3) 2 (11.8) 12 (29.3) 0.31
Bronchial asthma, n (%) 12 (20.0) 3 (17.6) 9 (22.0) 1.00
COPDa, n (%) 14 (23.3) 3 (17.6) 11 (26.8) 0.74
Liver cirrhosis, n (%) 0 (0.0) 0 (0.0) 0 (0.0) -
Renal failure, n (%) 10 (16.7) 2 (11.8) 8 (19.5) 0.71
Heart failure, n (%) 7 (11.7) 1 (5.9) 6 (14.6) 0.66
Malignant neoplasm, n (%) 19 (31.7) 4 (23.5) 15 (36.6) 0.54
Patients vaccinated against S. pneumoniae, n (%) 13 (21.7) 1 (5.9) 12 (29.3) 0.087
Patients with prior antibiotic therapy, n (%) 23 (38.3) 4 (23.5) 19 (46.3) 0.16
Body temperature, °C, median (range) 37.6 (35.6–40.2) 37.8 (36.3–39.9) 37.6 (35.6–40.2) 0.71
White blood cells, /μL, median (range) 10,850 (2000–30,700) 11,900 (6100–30,700) 10,700 (2000–25,100) 0.52
C-reactive protein, mg/dL, median (range) 12.23 (0.12–40.73) 15.11 (0.92–36.7) 12.14 (0.12–40.73) 0.046
PORTb score, points, median (range) 111.5 (32–236) 87 (38–236) 124 (32–186) 0.10
aChronic obstructive pulmonary disease
bPneumonia Patient Outcomes Research Team
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Patients with positive results using
RAPIRUN with nasopharyngeal swabs
(n = 4)
Age, years, median (range) 78 (28–96) 79.5 (76–87)
Male sex, n (%) 7 (41.2) 0 (0.0)
Nursing home residents, n (%) 0 (0.0) 0 (0.0)
Smoking history, n (%) 7 (41.2) 0 (0.0)
Patients with underlying disease
Diabetes mellitus, n (%) 2 (11.8) 0 (0.0)
Bronchial asthma, n (%) 3 (17.6) 0 (0.0)
COPDa, n (%) 3 (17.6) 0 (0.0)
Liver cirrhosis, n (%) 0 (0.0) 0 (0.0)
Renal failure, n (%) 2 (11.8) 0 (0.0)
Heart failure, n (%) 1 (5.9) 0 (0.0)
Malignant neoplasm, n (%) 4 (23.5) 1 (25.0)
Patients vaccinated against S. pneumoniae, n (%) 1 (5.9) 1 (25.0)
Patients with prior antibiotic therapy, n (%) 4 (23.5) 0 (0.0)
Body temperature, °C, median (range) 37.8 (36.3–39.9) 39.1 (38.3–39.4)
White blood cells, /μL, median (range) 11,900 (6100–30,700) 9000 (6600–13,300)
C-reactive protein, mg/dL, median (range) 15.11 (0.92–36.7) 17.5 (14.1–34.7)
PORTb score, points, median (range) 87 (38–236) 92.5 (86–101)
aChronic obstructive pulmonary disease
bPneumonia Patient Outcomes Research Team
Table 3 Results of sputum culture and antigen detection using urine, sputum, and nasopharyngeal swab samples for 17 patients
diagnosed with pneumococcal pneumonia
No. Sputum culture Urinary antigen Sputum antigen Nasopharyngeal swabs Nasopharyngeal culture
1 Streptococcus pneumoniae - + - S. pneumoniae
2 Klebsiella pneumoniae - + - K. pneumoniae
3 Staphylococcus aureus + + + S. aureus
4 Moraxella + - - α Streptococcus
5 S. pneumoniae + + - S. pneumoniae
6 Neisseria spp + - - α Streptococcus
7 S. pneumoniae + + + S. pneumoniae
8 S. pneumoniae - + - α Streptococcus
9 S. pneumoniae + + + S. pneumoniae
10 S. pneumoniae, Escherichia coli + + - S. aureus
11 Not detected + - - S. aureus
12 S. pneumoniae + + - α Streptococcus
13 S. pneumoniae + + - α Streptococcus
14 Not detected + - - S. aureus
15 S. pneumoniae + + - α Streptococcus
16 Not detected + - - α Streptococcus
17 S. pneumoniae + + + α Streptococcus
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children (under 15 years of age). The results of the
present study suggest that RAPIRUN with nasopharyn-
geal swabs should not be used for the diagnosis of
pneumococcal pneumonia in adult patients. The dis-
crepancy of result between RAPIRUN with nasopharyn-
geal swab and nasopharyngeal culture might suggest
that nasopharyngeal swab sample from adult patients
with pneumonia are not useful.
In this study, 17 patients were diagnosed with pneumo-
coccal pneumonia using BinaxNOW, RAPIRUN with a
sputum sample, or sputum culture. However, these cases
may include false positive cases, for example, due to
colonization or cross-reaction of antigens, and false nega-
tive cases. Because it is very difficult to detect the causa-
tive pathogen of pneumonia, clinical data, gram staining
of sputum, or radiographic patterns should be considered
in addition to sputum culture and rapid antigen detection
kits. It might not be suitable to base a diagnosis only on
the results of RAPIRUN with a nasopharyngeal swab in
adult patients because of low sensitivity.
This study only included inpatients with fairly severe
cases of pneumonia. Further studies targeting not only in-
patients but also outpatients with pneumonia are
required. The small number of pneumococcal pneumonia
patients is also a limitation of this study. Further investiga-
tion with larger number of participants would be required.
Conclusions
In conclusion, RAPIRUN exhibited low sensitivity for the
diagnosis of pneumococcal pneumonia when used with
nasopharyngeal swab samples from adult patients. The
causative pathogen of pneumonia should be identified
using not only sputum culture or rapid antigen detection
kits but also clinical features or gram staining of sputum.
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The St. Luke’s International Hospital Research Ethics
Committee approved all aspects of this study (approval
number 11-R127, approval date October 24, 2011).
Written informed consent was obtained from all
participants.
Abbreviations
COPD: chronic obstructive pulmonary disease; PORT: Pneumonia Patient
Outcomes Research Team.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SS contributed to the planning of the study, implementation, data
interpretation, and manuscript preparation. NN provided scientific leadership,
study implementation, data interpretation, and manuscript preparation. TJ
contributed to study design, implementation, data interpretation. YY, GI, and
YT contributed to data collection and study implementation. NU contributed
to data analysis and interpretation. NC contributed to directing the study,
data collection and study implementation. All authors read and approved
the final manuscript.
Acknowledgements
We thank Ms. Kumiko Soejima for assisting with the statistical analysis.
Funding
The authors declare that there are no sources of funding in this study.
Received: 14 February 2016 Accepted: 21 April 2016
References
1. WHO. Top 10 causes of death http://www.who.int/gho/mortality_burden_
disease/causes_death/top_10/en/ Accessed 27 April 2016.
2. Welte T, Torres A, Nathwani D. Clinical and economic burden of
community-acquired pneumonia among adults in Europe. Thorax.
2012;67(1):71–9.
3. Rozenbaum MH, Pechlivanoglou P, van der Werf TS, Lo-Ten-Foe JR, Postma MJ,
Hak E. The role of Streptococcus pneumoniae in community-acquired
pneumonia among adults in Europe: a meta-analysis. Eur J Clin Microbiol
Infect Dis. 2013;32(3):305–16.
4. Peto L, Nadjm B, Horby P, Ngan TT, van Doorn R, Van Kinh N, et al. The
bacterial aetiology of adult community-acquired pneumonia in Asia: a
systematic review. Trans R Soc Trop Med Hyg. 2014;108(6):326–37.
5. Cutts FT, Zaman SM, Enwere G, Jaffar S, Levine OS, Okoko JB, et al. Efficacy
of nine-valent pneumococcal conjugate vaccine against pneumonia and
invasive pneumococcal disease in The Gambia: randomised, double-blind,
placebo-controlled trial. Lancet. 2005;365(9465):1139–46.
6. Gutierrez F, Masia M, Rodriguez JC, Ayelo A, Soldan B, Cebrian L, et al.
Evaluation of the immunochromatographic Binax NOW assay for detection
of Streptococcus pneumoniae urinary antigen in a prospective study of
community-acquired pneumonia in Spain. Clin Infect Dis. 2003;36(3):286–92.
7. Dominguez J, Gali N, Blanco S, Pedroso P, Prat C, Matas L, et al. Detection of
Streptococcus pneumoniae antigen by a rapid immunochromatographic assay
in urine samples. Chest. 2001;119(1):243–9.
8. Horita N, Miyazawa N, Kojima R, Kimura N, Inoue M, Ishigatsubo Y, et al.
Sensitivity and specificity of the Streptococcus pneumoniae urinary antigen
test for unconcentrated urine from adult patients with pneumonia: a meta-
analysis. Respirology. 2013;18(8):1177–83.
9. Ehara N, Fukushima K, Kakeya H, Mukae H, Akamatsu S, Kageyama A, et al. A
novel method for rapid detection of Streptococcus pneumoniae antigen in
sputum and its application in adult respiratory tract infections. J Med
Microbiol. 2008;57(Pt 7):820–6.
10. Izumikawa K, Akamatsu S, Kageyama A, Okada K, Kazuyama Y, Takayanagi N,
et al. Evaluation of a rapid immunochromatographic ODK0501 assay for
detecting Streptococcus pneumoniae antigen in sputum samples from
patients with lower respiratory tract infection. Clin Vaccine Immunol. 2009;
16(5):672–8.
11. Mukae H, Yatera K, Noguchi S, Kawanami T, Yamasaki K, Tokuyama S, et al.
Evaluation of a rapid immunochromatographic ODK0501 assay for detecting
Streptococcus pneumoniae antigens in the sputum of pneumonia patients
with positive S. pneumoniae urinary antigens. J Infect Chemother. 2015;21(3):
176–81.
12. Iwata S, Matsubara K, Kawamura N, Shimizu K, Azumagawa K,
Morinobu T, et al. Clinical performance evaluation of Streptococcus
pneumoniae antigen detection kit ODK0501 in childhood respiratory
tract infections. J Pediatr Infect Dis Immunol. 2011;23(1):3–9.
13. Barrett-Connor E. The nonvalue of sputum culture in the diagnosis of
pneumococcal pneumonia. Am Rev Respir Dis. 1971;103(6):845–8.
14. Lentino JR, Lucks DA. Nonvalue of sputum culture in the management of
lower respiratory tract infections. J Clin Microbiol. 1987;25(5):758–62.
Suzuki et al. Multidisciplinary Respiratory Medicine  (2016) 11:25 Page 5 of 5
